Study of Effective Treatment of Genital Herpes in Women in Ukraine

Speaker(s)

Zaliska O1, Matvienko O1, Matvienko Y1, Maksymovych N1, Malachynska M2, Minko L3
1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 2Danylo Halytsky Lviv National Medical University, Lviv Regional Reproductive Health Centre, Lviv, Lviv, Ukraine, 3Lviv National Medical University, Lviv, Ukraine

OBJECTIVES: Genital herpes is a common sexually transmitted disease caused by the herpes simplex virus (HSV), characterized by lifelong infection,periodic reactivation. Worldwide, more than 400 million people have genital herpes caused by HSV-2. For patients with genital HSV-1 infection or those with asymptomatic HSV-2 infection, suppressive therapy may be considered for those with significant psychosocial distress due to genital herpes and suspected sexual partner infection.There are several strategies for the use of antiherpetic drugs (acyclovir, famciclovir, valacyclovir), which have been studied and tested in cases of first infection with genital herpes, episodic and suppressive cure. In Ukraine is registered medicine Famciclovir from domestic producer.

METHODS: We analysed databases Google Scholar, Research 4 life, Science Direct, PubMed, Scopus.Using content analysis, methods of comparative analysis of the medical literature devoted to modern approaches to the treatment of genital herpes in women was analyzed.

RESULTS: We found 12 publications by foreign authors, which were selected and processed based on their relevance to the chosen topic, and information on the effectiveness of the use of the antiviral agent famciclovir (Virostat, Ukraine) in one's own practice was provided. There was no difference in viral shedding or lesion severity with oral or vaginal tenofovir versus placebo. Tenofovir is not recommended for the treatment of HSV-2 infection. Our clinical experience allows to recommend the use of the Ukrainian medicine Virostat for the effective treatment of HSV infection in women.There is recurrence of genital herpes in doses 125.0 mg twice for 5 days. Treatment should be started in the prodromal period (tingling, itching, heartburn, pain), or immediately after the first manifestation of the disease in patients with weakened immunity: 500.0 mg twice a day.

CONCLUSIONS: Considering literature data, clinical experience of using the domestic medicine is effective for various clinical manifestations of genital herpes.So it can recommend more implementation in local formularies.

Code

HSD121

Disease

Reproductive & Sexual Health